Baird lowered the firm’s price target on Boston Scientific (BSX) to $101 from $118 and keeps an Outperform rating on the shares. The firm said the weakness in the shares following its EP/Watchman miss, is a buying opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $120 from $140 at UBS
- Boston Scientific price target lowered to $102 from $130 at Citi
- Boston Scientific price target lowered to $112 from $131 at Canaccord
- Spotify, Boston Scientific removed from ‘US 1 List’ at BofA
- Boston Scientific’s Earnings Call Highlights Durable Growth